PDGF receptors as targets in tumor treatment
- PMID: 17419949
- DOI: 10.1016/S0065-230X(06)97011-0
PDGF receptors as targets in tumor treatment
Abstract
Signaling through platelet-derived growth factor (PDGF) receptors contributes to multiple tumor-associated processes. The recent introduction of clinically useful PDGF inhibitors have the last years validated PDGF receptors in malignant and stromal cells as relevant cancer drug targets. Mutational activation of PDGF receptor signaling in malignant cells has been described in some rare tumor types such as dermatofibrosarcoma protuberans, a subset of GISTs, and some hematologic malignancies. Furthermore, expression of PDGF receptors on pericytes is a common characteristic of solid tumors. The clinical efficacy of novel multikinase inhibitors, such as sunitinib and sorafenib, most likely involves targeting of PDGF receptor-dependent pericytes. Preclinical studies suggest that targeting of stromal PDGF receptors might also constitute a novel strategy to enhance tumor drug uptake. Finally, recent studies have implied both pro- and antimetastatic effects of PDGF receptors on malignant and stromal cells. The studies on the roles of PDGF receptors in cancer signaling are thus presently in a dynamic phase where collaborations between oncologists, pathologists, and tumor biologists are predicted to be highly productive.
Similar articles
-
Functions of paracrine PDGF signaling in the proangiogenic tumor stroma revealed by pharmacological targeting.PLoS Med. 2008 Jan 29;5(1):e19. doi: 10.1371/journal.pmed.0050019. PLoS Med. 2008. PMID: 18232728 Free PMC article.
-
Targeting PDGF signaling in carcinoma-associated fibroblasts controls cervical cancer in mouse model.PLoS Med. 2008 Jan 29;5(1):e24. doi: 10.1371/journal.pmed.0050024. PLoS Med. 2008. PMID: 18232729 Free PMC article.
-
Increased sensitivity to the platelet-derived growth factor (PDGF) receptor inhibitor STI571 in chemoresistant glioma cells is associated with enhanced PDGF-BB-mediated signaling and STI571-induced Akt inactivation.J Cell Physiol. 2006 Jul;208(1):220-8. doi: 10.1002/jcp.20659. J Cell Physiol. 2006. PMID: 16575905
-
PDGF receptors-mediators of autocrine tumor growth and regulators of tumor vasculature and stroma.Cytokine Growth Factor Rev. 2004 Aug;15(4):275-86. doi: 10.1016/j.cytogfr.2004.03.002. Cytokine Growth Factor Rev. 2004. PMID: 15207817 Review.
-
Imatinib and prostate cancer: lessons learned from targeting the platelet-derived growth factor receptor.Expert Opin Investig Drugs. 2013 Jun;22(6):787-94. doi: 10.1517/13543784.2013.787409. Epub 2013 Apr 1. Expert Opin Investig Drugs. 2013. PMID: 23540855 Review.
Cited by
-
Cancer-associated fibroblasts as targets for immunotherapy.Immunotherapy. 2012 Nov;4(11):1129-38. doi: 10.2217/imt.12.112. Immunotherapy. 2012. PMID: 23194363 Free PMC article. Review.
-
Synergistic antiproliferative effect of imatinib and adriamycin in platelet-derived growth factor receptor-expressing osteosarcoma cells.Cancer Sci. 2015 Jul;106(7):875-82. doi: 10.1111/cas.12686. Epub 2015 May 26. Cancer Sci. 2015. PMID: 25940371 Free PMC article.
-
Stromal integrin α11 regulates PDGFR-β signaling and promotes breast cancer progression.J Clin Invest. 2019 Jul 9;129(11):4609-4628. doi: 10.1172/JCI125890. J Clin Invest. 2019. PMID: 31287804 Free PMC article.
-
Minimal cross-intolerance with nilotinib in patients with chronic myeloid leukemia in chronic or accelerated phase who are intolerant to imatinib.Blood. 2011 May 26;117(21):5600-6. doi: 10.1182/blood-2010-11-318949. Epub 2011 Apr 5. Blood. 2011. PMID: 21467546 Free PMC article. Clinical Trial.
-
Directed migration of mesenchymal cells: where signaling and the cytoskeleton meet.Curr Opin Cell Biol. 2014 Oct;30:74-82. doi: 10.1016/j.ceb.2014.06.005. Epub 2014 Jul 5. Curr Opin Cell Biol. 2014. PMID: 24999834 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
